WO2008139703A1 - 肺疾患治療薬 - Google Patents

肺疾患治療薬 Download PDF

Info

Publication number
WO2008139703A1
WO2008139703A1 PCT/JP2008/001081 JP2008001081W WO2008139703A1 WO 2008139703 A1 WO2008139703 A1 WO 2008139703A1 JP 2008001081 W JP2008001081 W JP 2008001081W WO 2008139703 A1 WO2008139703 A1 WO 2008139703A1
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
agent
pulmonary disease
pulmonary diseases
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/001081
Other languages
English (en)
French (fr)
Inventor
Kensuke Egashira
Junji Kojima
Megumi Sakamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyushu University NUC
Kowa Co Ltd
Original Assignee
Kyushu University NUC
Kowa Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyushu University NUC, Kowa Co Ltd filed Critical Kyushu University NUC
Priority to JP2009513998A priority Critical patent/JP4896220B2/ja
Priority to ES08751606T priority patent/ES2425969T3/es
Priority to EP08751606.8A priority patent/EP2140882B1/en
Priority to KR1020097021959A priority patent/KR101530393B1/ko
Priority to CA2685054A priority patent/CA2685054C/en
Priority to HK10108116.0A priority patent/HK1141708B/xx
Priority to US12/596,996 priority patent/US20100086615A1/en
Priority to CN2008800137806A priority patent/CN101668542B/zh
Publication of WO2008139703A1 publication Critical patent/WO2008139703A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

　有効性が高く、かつ副作用の少ない肺疾患治療薬の提供。 　ＨＭＧ－ＣｏＡリダクターゼ阻害剤を含む生体適合性ポリマーナノ粒子を含有する気管内投与用肺疾患治療薬。
PCT/JP2008/001081 2007-04-27 2008-04-25 肺疾患治療薬 Ceased WO2008139703A1 (ja)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2009513998A JP4896220B2 (ja) 2007-04-27 2008-04-25 肺疾患治療薬
ES08751606T ES2425969T3 (es) 2007-04-27 2008-04-25 Agente para el tratamiento de enfermedades pulmonares
EP08751606.8A EP2140882B1 (en) 2007-04-27 2008-04-25 Agent for treatment of pulmonary disease
KR1020097021959A KR101530393B1 (ko) 2007-04-27 2008-04-25 폐질환 치료약
CA2685054A CA2685054C (en) 2007-04-27 2008-04-25 Agent for treatment of pulmonary disease
HK10108116.0A HK1141708B (en) 2007-04-27 2008-04-25 Agent for treatment of pulmonary disease
US12/596,996 US20100086615A1 (en) 2007-04-27 2008-04-25 Agent for treatment of pulmonary disease
CN2008800137806A CN101668542B (zh) 2007-04-27 2008-04-25 肺病治疗药

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007-119553 2007-04-27
JP2007119553 2007-04-27
JP2007155816 2007-06-13
JP2007-155816 2007-06-13

Publications (1)

Publication Number Publication Date
WO2008139703A1 true WO2008139703A1 (ja) 2008-11-20

Family

ID=40001929

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/001081 Ceased WO2008139703A1 (ja) 2007-04-27 2008-04-25 肺疾患治療薬

Country Status (9)

Country Link
US (1) US20100086615A1 (ja)
EP (1) EP2140882B1 (ja)
JP (1) JP4896220B2 (ja)
KR (1) KR101530393B1 (ja)
CN (1) CN101668542B (ja)
CA (1) CA2685054C (ja)
ES (1) ES2425969T3 (ja)
PT (1) PT2140882E (ja)
WO (1) WO2008139703A1 (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014516044A (ja) * 2011-05-25 2014-07-07 ユストゥス−リービッヒ−ウニヴェルジテート・ギーセン 肺に投与するための活性成分を含有する生体適合性ナノポリマー粒子
JP2015164420A (ja) * 2014-02-10 2015-09-17 公立大学法人首都大学東京 クロマチン構造制御剤
WO2021167088A1 (ja) * 2020-02-21 2021-08-26 良和 中岡 肺高血圧症改善用組成物、肺高血圧症の予後予測方法、肺高血圧症の重症度判定補助方法および肺高血圧症の診断補助方法
EP4179069A4 (en) * 2020-07-09 2024-10-02 Remedy Cell Ltd. METHODS FOR THE TREATMENT OF ACUTE RESPIRATORY INFLAMMATION AND CYTOKINE STORM SYNDROME

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2526927A1 (de) * 2011-05-25 2012-11-28 Justus-Liebig-Universität Gießen Biokompatible Nano- und Mikropartikel beschichtet mit Stabilisatoren für die pulmonale Applikation
EP3777890A1 (en) * 2014-11-10 2021-02-17 Masaaki II Stem cells containing statin-encapsulated nanoparticles
EP3453391A4 (en) * 2016-05-06 2020-01-08 Educational Foundation of Osaka Medical and Pharmaceutical University PREPARATION OF NANOPARTICLES CONTAINING A STATINE TO IMPROVE THE FUNCTION OF STEM CELLS TO TREAT INFLAMMATORY DISEASE, AND FUNCTIONALLY IMPROVED STEM CELLS CONTAINING IT TO TREAT INFLAMMATORY DISEASE
WO2019162951A1 (en) * 2018-02-26 2019-08-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Drug delivery systems
JP2019196342A (ja) * 2018-05-10 2019-11-14 学校法人大阪医科薬科大学 スタチン封入ナノ粒子製剤、それを含有する歯髄由来幹細胞及びそれを含む細胞製剤。
US20230014352A1 (en) * 2019-03-29 2023-01-19 The Regents Of The University Of California Inhaled statins as bronchodilators to improve lung function in respiratory diseases

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
JPS56122375A (en) 1980-02-04 1981-09-25 Merck & Co Inc Novel antihypercholesteremic compound* its intermediate and its manufacture
JPS572240A (en) 1980-06-06 1982-01-07 Sankyo Co Ltd Ml-236b derivative
US4346227A (en) 1980-06-06 1982-08-24 Sankyo Company, Limited ML-236B Derivatives and their preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
JPS60500015A (ja) 1982-11-22 1985-01-10 サンド・アクチエンゲゼルシヤフト メバロラクトン同族体とその誘導体、これらの製造法およびこれらを含有する製薬学的組成物
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US4739073A (en) 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
EP0304063A2 (en) 1987-08-20 1989-02-22 Nissan Chemical Industries Ltd. Quinoline type mevalonolactones
JPH0358967A (ja) 1989-07-21 1991-03-14 Warner Lambert Co 〔Ｒ―（Ｒ‖，Ｒ‖）〕―２―（４―フルオロフエニル）―β，δ―ジヒドロキシ―５―（１―メチルエチル）―３―フエニル―４―〔（フエニルアミノ）カルボニル〕―１Ｈ―ピロール―１―ヘプタン酸、そのラクトン体およびその塩
US5102888A (en) 1987-08-20 1992-04-07 Nissan Chemical Industries Ltd. Quinoline type mevalonolactones useful for treating hyperlipidemia and related diseases
JPH05178841A (ja) 1991-07-01 1993-07-20 Shionogi & Co Ltd ピリミジン誘導体
WO2000048626A2 (en) * 1999-02-17 2000-08-24 University Of Washington Aerosol compositions of hmg-coa reductase inhibitors for inhibiting inflammation associated with pulmonary disease
JP2003275281A (ja) 2002-03-20 2003-09-30 Hosokawa Micron Corp 薬物含有複合粒子の製造方法
JP2004521152A (ja) * 2000-05-16 2004-07-15 サントル ナシオナル ドゥ ラ ルシェルシェサイアンティフィク（セエヌエールエス） 生分解ポリマーを基にした材料及びその製造方法
JP2004262810A (ja) 2003-02-28 2004-09-24 Hosokawa Funtai Gijutsu Kenkyusho:Kk 薬物含有複合粒子の製造方法および経肺製剤
JP2006321763A (ja) 2005-05-20 2006-11-30 Hosokawa Funtai Gijutsu Kenkyusho:Kk 生体適合性ナノ粒子及びその製造方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
WO2003049701A2 (en) * 2001-12-10 2003-06-19 Spherics, Inc. Methods and products useful in the formation and isolation of microparticles
WO2003077886A1 (en) * 2002-03-20 2003-09-25 Hosokawa Micron Corporation Method of manufacturing chemical-containing composite particles
WO2003103640A1 (en) * 2002-06-10 2003-12-18 Elan Pharma International, Ltd Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (“statins”), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
US20050119330A1 (en) * 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
US20040224030A1 (en) * 2003-05-06 2004-11-11 Shastri Venkatram R. Microsphere delivery systems
US7183285B2 (en) * 2004-04-29 2007-02-27 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20050245905A1 (en) * 2004-04-30 2005-11-03 Schmidt Steven P Local drug-delivery system
US7651770B2 (en) * 2005-12-16 2010-01-26 The University Of Kansas Nanoclusters for delivery of therapeutics
GB0619500D0 (en) * 2006-10-03 2006-11-08 Univ Keele Treatment of fibrosis

Patent Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
JPS57163374A (en) 1979-06-15 1982-10-07 Merck & Co Inc Hypocholesterolemic fermentation product and manufacture
JPS56122375A (en) 1980-02-04 1981-09-25 Merck & Co Inc Novel antihypercholesteremic compound* its intermediate and its manufacture
JPS572240A (en) 1980-06-06 1982-01-07 Sankyo Co Ltd Ml-236b derivative
US4346227A (en) 1980-06-06 1982-08-24 Sankyo Company, Limited ML-236B Derivatives and their preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
JPS60500015A (ja) 1982-11-22 1985-01-10 サンド・アクチエンゲゼルシヤフト メバロラクトン同族体とその誘導体、これらの製造法およびこれらを含有する製薬学的組成物
US4739073A (en) 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
JP2569746B2 (ja) 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
US5102888A (en) 1987-08-20 1992-04-07 Nissan Chemical Industries Ltd. Quinoline type mevalonolactones useful for treating hyperlipidemia and related diseases
EP0304063A2 (en) 1987-08-20 1989-02-22 Nissan Chemical Industries Ltd. Quinoline type mevalonolactones
US5856336A (en) 1987-08-20 1999-01-05 Nissan Chemical Industries Ltd. Quinoline type mevalonolactones
JPH0358967A (ja) 1989-07-21 1991-03-14 Warner Lambert Co 〔Ｒ―（Ｒ‖，Ｒ‖）〕―２―（４―フルオロフエニル）―β，δ―ジヒドロキシ―５―（１―メチルエチル）―３―フエニル―４―〔（フエニルアミノ）カルボニル〕―１Ｈ―ピロール―１―ヘプタン酸、そのラクトン体およびその塩
US5273995A (en) 1989-07-21 1993-12-28 Warner-Lambert Company [R-(R*R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino) carbonyl]- 1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof
JPH05178841A (ja) 1991-07-01 1993-07-20 Shionogi & Co Ltd ピリミジン誘導体
US5260440A (en) 1991-07-01 1993-11-09 Shionogi Seiyaku Kabushiki Kaisha Pyrimidine derivatives
WO2000048626A2 (en) * 1999-02-17 2000-08-24 University Of Washington Aerosol compositions of hmg-coa reductase inhibitors for inhibiting inflammation associated with pulmonary disease
JP2004521152A (ja) * 2000-05-16 2004-07-15 サントル ナシオナル ドゥ ラ ルシェルシェサイアンティフィク（セエヌエールエス） 生分解ポリマーを基にした材料及びその製造方法
JP2003275281A (ja) 2002-03-20 2003-09-30 Hosokawa Micron Corp 薬物含有複合粒子の製造方法
JP2004262810A (ja) 2003-02-28 2004-09-24 Hosokawa Funtai Gijutsu Kenkyusho:Kk 薬物含有複合粒子の製造方法および経肺製剤
JP2006321763A (ja) 2005-05-20 2006-11-30 Hosokawa Funtai Gijutsu Kenkyusho:Kk 生体適合性ナノ粒子及びその製造方法

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
"Nanospheres tailored to inhalation devices", MANUFACTURING CHEMIST, vol. 77, no. 9, September 2006 (2006-09-01), pages 75 - 76, 78, XP008119399 *
BANDO Y. ET AL.: "Choki Kecchu Tairyusei o Mokuteki to shita Seibunkaisei Kobunshi Nanosphere no Sekkei", THE PHARMACEUTICAL SOCIETY OF JAPAN NENKAI YOSHISHU, vol. 127TH, no. 3, 5 March 2007 (2007-03-05), pages 126 + ABSTR. NO. 29P1-AM293 *
GINA GUIDELINE, 2006
GOLD GUIDELINE, 2006
GOODMAN; GILMAN: "Pharmacological Basis of Therapeutics", 2001, MCGRAW HILL
HOTHERSALL E. ET AL., THORAX, vol. 61, 2006, pages 729 - 734
JOURNAL OF THE SOCIETY OF POWDER TECHNOLOGY, vol. 42, no. 11, 2005, pages 765 - 772
MANCINI GBJ ET AL., J. AM. COLL. CARDIOL., vol. 47, 2006, pages 2554 - 2560
MIZOE T. ET AL.: "Nano Ryushi Gan'yu Microsphere no Sekkei to DDS eno Oyo", SOCIETY OF POWDER TECHNOLOGY, JAPAN.FUNTAI KOGYO GIJUTSU KYOKAI GIJUTSU TORONKAI.TEXT, vol. 41ST, 2006, pages 19 - 20 *
OURNAL OF THE SOCIETY OF POWDER TECHNOLOGY, vol. 42, 2005, pages 765 - 772
POYNER E.A. ET AL.: "A comparative study on the pulmonary delivery of tobramycin encapsulated into liposomes and PLA microspheres following intravenous and endotracheal delivery", JOURNAL OF CONTROLLED RELEASE, vol. 35, no. 1, July 1995 (1995-07-01), pages 41 - 48, XP004037491 *
See also references of EP2140882A4
SOYSETH V. ET AL., EUR. RESPIR. J., vol. 29, 2007, pages 279 - 283
WALTER N. ET AL., PROC. AM. THORAC. SOC., vol. 3, 2006, pages 330 - 338

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014516044A (ja) * 2011-05-25 2014-07-07 ユストゥス−リービッヒ−ウニヴェルジテート・ギーセン 肺に投与するための活性成分を含有する生体適合性ナノポリマー粒子
JP2015164420A (ja) * 2014-02-10 2015-09-17 公立大学法人首都大学東京 クロマチン構造制御剤
WO2021167088A1 (ja) * 2020-02-21 2021-08-26 良和 中岡 肺高血圧症改善用組成物、肺高血圧症の予後予測方法、肺高血圧症の重症度判定補助方法および肺高血圧症の診断補助方法
EP4179069A4 (en) * 2020-07-09 2024-10-02 Remedy Cell Ltd. METHODS FOR THE TREATMENT OF ACUTE RESPIRATORY INFLAMMATION AND CYTOKINE STORM SYNDROME

Also Published As

Publication number Publication date
US20100086615A1 (en) 2010-04-08
CA2685054C (en) 2014-11-04
EP2140882B1 (en) 2013-08-14
PT2140882E (pt) 2013-09-30
KR101530393B1 (ko) 2015-06-19
JP4896220B2 (ja) 2012-03-14
EP2140882A4 (en) 2010-05-26
CN101668542B (zh) 2012-06-27
JPWO2008139703A1 (ja) 2010-07-29
ES2425969T3 (es) 2013-10-18
CN101668542A (zh) 2010-03-10
EP2140882A1 (en) 2010-01-06
KR20100015758A (ko) 2010-02-12
CA2685054A1 (en) 2008-11-20
HK1141708A1 (en) 2010-11-19

Similar Documents

Publication Publication Date Title
WO2008139703A1 (ja) 肺疾患治療薬
WO2009064388A3 (en) Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders
WO2009054479A1 (ja) スピロ環化合物及びその医薬用途
WO2008070129A3 (en) Compositions and methods for the treatment of inflammatory disease
WO2010128050A3 (en) Dihydroorotate - dehydrogenasee inhibitors as virostatic compounds
WO2012021629A3 (en) Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
WO2007135527A3 (en) Benzimidazolyl compounds
WO2007104789A3 (en) Amylin derivatives
NZ589764A (en) NMDA receptor antagonists for the treatment of neuropsychiatric disorders
WO2008040548A3 (en) Treatment for non-alcoholic-steatohepatitis
WO2007087395A3 (en) UNSATURATED mTOR INHIBITORS
WO2009017837A3 (en) Sublingual fentanyl spray
WO2008132234A3 (en) Rna antagonist compounds for the modulation of beta-catenin
EP1937633B8 (en) Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
WO2008022024A3 (en) Imidazole amines as inhibitors of beta-secretase
WO2010031825A3 (en) Methods and compositions for the treatment of cancer
WO2007138282A3 (en) Bi-aryl or aryl-heteroaryl substituted indoles
WO2009051119A1 (ja) ピリミジルインドリン化合物
WO2010066629A3 (en) Novel azaindoles
WO2011058027A3 (en) N-9-substituted purine compounds, compositions and methods of use
WO2009041663A1 (ja) 皮膚疾患の予防及び／または治療剤
WO2011026911A8 (en) Bipyridines useful for the treatment of proliferative diseases
WO2009134076A3 (ko) 방출성이 제어된 안지오텐신 - II - 수용체 차단제와 H M G - C o A 환원 효소 억제제의 복합제 조성물
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
WO2008009210A8 (fr) Composés de dihydropyrimidine optiquement purs et leurs utilisations dans la fabrication d'un médicament pour traiter ou prévenir des viroses

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880013780.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08751606

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009513998

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008751606

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20097021959

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2685054

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE